{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-003356","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.326252+00:00","generated_at":"2026-06-27T00:05:23.239002+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Design Therapeutics reports FY2021 net loss $35.5M, IND cleared for DT-216 Phase 1 trial","bullets":["Net loss $35.5M for FY2021 ($11.1M in Q4); cash and investments $384.1M at Dec 31, 2021.","IND for DT-216 (Friedreich Ataxia) cleared by FDA; Phase 1 trial to begin shortly.","Appointed Dr. Jae Kim as Chief Medical Officer to lead clinical development.","Preclinical data on GeneTAC molecules for Fuchs endothelial corneal dystrophy to be presented at ARVO May 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-003356","json":"https://secwatch.observer/filing/0000950170-22-003356.json","markdown":"https://secwatch.observer/filing/0000950170-22-003356.md","text":"https://secwatch.observer/filing/0000950170-22-003356.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000095017022003356/0000950170-22-003356-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000095017022003356/dsgn-20220310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:05:23.239002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}